Amicus Therapeutics Inc
NASDAQ:FOLD

Watchlist Manager
Amicus Therapeutics Inc Logo
Amicus Therapeutics Inc
NASDAQ:FOLD
Watchlist
Price: 9.21 USD -0.22%
Market Cap: 2.8B USD

Amicus Therapeutics Inc
Unrealized Security Profit/Loss

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Amicus Therapeutics Inc
Unrealized Security Profit/Loss Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Unrealized Security Profit/Loss CAGR 3Y CAGR 5Y CAGR 10Y
Amicus Therapeutics Inc
NASDAQ:FOLD
Unrealized Security Profit/Loss
-$188k
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Unrealized Security Profit/Loss
$51.2m
CAGR 3-Years
N/A
CAGR 5-Years
120%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Amicus Therapeutics Inc
Glance View

Market Cap
2.8B USD
Industry
Biotechnology

In the ever-evolving landscape of biotech, Amicus Therapeutics Inc. stands as a beacon of innovation, rooted deeply in the realm of rare and orphan diseases. Founded with the mission to harness advanced therapies for conditions with limited treatment options, the company has carved a niche in developing treatments that hinge on cutting-edge science. Specifically, Amicus focuses on creating next-generation therapies involving chaperone proteins and genetic medicines. These specialized therapies work by stabilizing and enhancing the function of faulty proteins that are hallmarks of many genetic disorders, thereby directly addressing the underlying causes of these conditions. Their portfolio, prominently featuring Galafold (migalastat) for Fabry disease, exemplifies their approach—leveraging precision medicine to cater to patients who have been underserved by traditional pharmaceutical models. Revenue generation for Amicus Therapeutics predominantly revolves around the commercialization of Galafold, which is approved in numerous global markets. Galafold offers a personalized approach, being targeted towards individuals with Fabry disease who possess amenable genetic mutations. This specificity not only underscores Amicus's commitment to precision therapeutics but also reinforces its competitive edge, as the treatment reduces the necessity for enzymatic replacement, a conventional route with broader systemic impacts. Beyond its current offerings, Amicus is strategically investing in its pipeline of gene therapies, aiming to provide breakthroughs in conditions like Pompe disease and other rare metabolic disorders. By enhancing existing therapies and fostering new breakthroughs, Amicus not only upholds its commitment to patient-centric solutions but also bolsters its financial sustainability through strategic innovation and market expansion.

FOLD Intrinsic Value
13.4 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Amicus Therapeutics Inc's Unrealized Security Profit/Loss?
Unrealized Security Profit/Loss
-188k USD

Based on the financial report for Sep 30, 2024, Amicus Therapeutics Inc's Unrealized Security Profit/Loss amounts to -188k USD.

What is Amicus Therapeutics Inc's Unrealized Security Profit/Loss growth rate?
Unrealized Security Profit/Loss CAGR 3Y
2%

Over the last year, the Unrealized Security Profit/Loss growth was 6%. The average annual Unrealized Security Profit/Loss growth rates for Amicus Therapeutics Inc have been 2% over the past three years .

Back to Top